Abstract:A novel style of versatile nano‐proteolysis targeting chimera is constructed by the incorporation of the BRD4 degrader dBET6, which aims to target both lung cancer cells and M2 tumor‐associated macrophages (TAMs) which favors the tumor‐promoting microenvironment. Specific degradation of BRD4 leads to substantial cell apoptosis of both lung cancer cells and TAMs, thereby remodeling the tumor microenvironment, which in turn, renders tumor shrinkage. This work proposes a novel approach for specifically delivering the BRD4 degrader to regress cancers. Recent evidence has indicated that overexpression of the epigenetic reader bromodomain‐containing protein 4 (BRD4) contributes to a poor prognosis of lung cancers, and the suppression of its expression promotes cell apoptosis and leads to tumor shrinkage. Proteolysis targeting chimera (PROTAC) has recently emerged as a promising therapeutic strategy with the capability to precisely degrade targeted proteins. Herein, a novel style of versatile nano‐PROTAC (CREATE (CRV‐LLC membrane/DS‐PLGA/dBET6)) is developed, which is constructed by using a pH/GSH (glutathione)‐responsive polymer (disulfide bond‐linked poly(lactic‐co‐glycolic acid), DS‐PLGA) to load BRD4‐targeted PROTAC (dBET6), followed by the camouflage with engineered lung cancer cell membranes with dual targeting capability. Notably, CREATE remarkably confers simultaneous targeting ability to lung cancer cells and tumor‐associated macrophages (TAMs). The pH/GSH‐responsive design improves the release of dBET6 payload from nanoparticles to induce pronounced apoptosis of both cells, which synergistically inhibits tumor growth in both subcutaneous and orthotopic tumor‐bearing mouse model. Furthermore, the efficient tumor inhibition is due to the direct elimination of lung cancer cells and TAMs, which remodels the tumor microenvironment. Taken together, the results elucidate the construction of a versatile nano‐PROTAC enables to eliminate both lung cancer cells and TAMs, which opens a new avenue for efficient lung cancer therapy via PROTAC.

Protocol for constructing tumor-targeting ANM-PROTACs for degradation of transcription factors

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Repurposing AS1411 for constructing ANM-PROTACs

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

MicroRNA‐Triggered Programmable DNA‐Encoded Pre‐PROTACs for Cell‐Selective and Controlled Protein Degradation

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

Conditionally Activatable Chimeras for Tumor-Specific Membrane Protein Degradation

Versatile Nano‐PROTAC‐Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

Precise Modulation of Protein Degradation by Smart PROTACs